Siemens net profit up 18 percent at Rs 219 crore in March quarter

Published On 2018-05-06 04:30 GMT   |   Update On 2018-05-06 04:30 GMT

New Delhi: Siemens posted 18 percent jump in its standalone net profit to Rs 219.7 crore in the quarter ended March 31, mainly on account of higher revenues.


The company had reported Rs 186.2 crore standalone net profit in the March quarter last year, Siemens Ltd said in a statement.


The company follows the financial year from October to September.


"For the second quarter of Financial Year 2018, ended March 31, 2018, Siemens Ltd registered a revenue of Rs 3,163.1 crore which amounts to a 10.6 percent increase in revenue (excluding from the revenue for the corresponding quarter of the previous year the impact of Excise Duty) over the same quarter in the preceding year," it said.




The company said that the new orders for the period stood at Rs 2,923.6 crore. There was an increase in orders of 22 percent in its base business (orders of value less than Rs 100 crore) for the second quarter of the financial year 2018 and 21 percent for the first half of 2017-18.


Large orders won during the second quarter of the financial year 2017 included an order from Power Grid Corporation for the Pugalur-Thrissur high-voltage direct current (HVDC) transmission system, it added.


"While our base business is growing satisfactorily, we do not see a pipeline of large and mega projects yet. Government tendering of large projects in the Energy business (Generation, Transmission & Distribution) has slowed down, though we do see private sector Capex beginning to expand.


Our focus continues on our Digitalisation initiatives and on ensuring operational excellence, both of which are reflected in our results," Siemens MD and CEO Sunil Mathur said in the statement.

Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News